Loading quotes...

Forecast

Buy	4
Hold	0
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Moleculin launches "CEO Corner" to expand investor communications

Moleculin has introduced the "CEO Corner" platform with CEO Walter Klemp to provide investors with detailed context on pipeline programs, clinical milestones and strategy via video contributions. Investors can submit questions and topics for future videos; the content is accessible on the company website. Moleculin is advancing, among others, Annamycin in a Phase‑3 study (MIRACLE), WP1066 and a portfolio of antimetabolites, but with a market capitalization of around USD 13 million and a steep share decline last year it faces financial challenges and a rapid cash burn. » More on de.investing.com

Financials

In the last quarter, Moleculin Biotech had revenue of €0 and net profit of -€5.73M

(EUR)	September 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-5.73M	73.51%
EBITDA	-5.83M	73.05%

Fundamentals

Metric	Value
Market capitalization	€7.28M
Number of shares	1.02M
52-week high/low	€208.19 - €2.92
Dividends	No
Beta	2.09
P/E ratio	-0.67
PEG ratio	0.00
P/B ratio	0.41
P/S ratio	0.00

Company profile

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.